García-Juárez I

Language: Spanish
References: 20
Page: 127-131
PDF size: 201.43 Kb.

Text Extraction

No abstract.

REFERENCES

1. Burra P, Rodríguez-Castro KI, Marchini F, Bonfante L, Furian L, Ferrarese A et al. Hepatitis C virus infection in end-stage renal disease and kidney transplantation. Transpl Int. 2014; 27: 877-891.

2. Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019; 15: 73-86.

3. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G et al. EASL recommendations on treatment of hepatitis c 2018. J Hepatol. 2018; 69: 461-511.

4. Kim SM, Song IH. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Korean J Intern Med. 2018; 33: 670-678.

5. Joglekar K, Eason JD, Molnar MZ. Do we really need more evidence to use hepatitis C positive donor kidney more liberally? Clin Kidney J. 2017; 10: 560-563.

6. Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant. 2018; 8: 84-96.

7. Cohen JB, Eddinger KC, Shelton B, Locke JE, Forde KA, Sawinski D. Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes. Clin Kidney J. 2017; 10: 564-572.

8. Fernandes AR, Laranjinha IJ, Birne R, Matias P, Jorge C, Adragão T et al. HCV-infected renal transplant recipients: our experience before the availability of new antiviral drugs. Int J Organ Transplant Med. 2017; 8 (2): 104-109.

9. Conti F, Serra C, Vukotic R, Felicani C, Mazzotta E, Gitto S et al. Assessment of liver fibrosis with elastography point quantification vs other noninvasive methods. Clin Gastroenterol Hepatol. 2019; 17: 510-517.

10. Buckley AJ, Thomas EL, Lessan N, Trovato FM, Trovato GM, Taylor-Robinson SD. Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. Diabetes Res Clin Pract. 2018; 144: 144-152.

11. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015; 63: 237-264.

12. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15: 11-20.

13. Sawinski D, Wyatt CM, Locke JE. Expanding the use of hepatitis C-viremic kidney donors. Kidney Int. 2017; 92: 1031-1033.

14. Kadatz M, Klarenbach S, Gill J, Gill JS. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am J Transplant. 2018; 18: 2457-2464.

15. Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus–infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018; 168: 533.

16. Prasad N, Patel M, Pandey A, Jaiswal A, Bhadauria D, Kaul A et al. Direct-acting antiviral agents in hepatitis C virus-infected renal allograft recipients: treatment and outcome experience from single center. Indian J Nephrol. 2018; 28: 220.

17. Aiza Haddad I, Ballesteros Amozurrutia A, Borjas Almaguer OD, Castillo Barradas M, Castro Narro G, Chávez Tapia N et al. Consenso Mexicano para el tratamiento de la hepatitis C. Revista de Gastroenterología de México. 2018; 83 (3): 275-324.

18. Gupta G, Zhang Y, Carroll NV, Sterling RK. Cost-effectiveness of hepatitis C-positive donor kidney transplantation for hepatitis C-negative recipients with concomitant direct-acting antiviral therapy. Am J Transplant. 2018; 18: 2496-505.

19. Sibulesky L, Kling CE, Blosser C, Johnson CK, Limaye AP, Bakthavatsalam R et al. Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider. Am J Transplant. 2018; 18: 2465-2472.

20. Gallegos-Orozco JF, Kim R, Thiesset HF, Hatch J, Lynch K, Chaly Jr T et al. Early results of pilot study using hepatitis C virus (HCV) positive kidneys to transplant HCV infected patients with end-stage renal disease allowing for successful interferon-free direct acting antiviral therapy after transplantation. Cureus. 2016; 8 (11): e890.